For adults with laboratory-confirmed Clostridioides difficile infection (CDI) at high risk for recurrence, high-dose VE303, a defined bacterial consortium of eight strains of commensal Clostridia, prevents recurrent CDI, ...
Apr 19, 2023
0
10
A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham health care system, tested the nasal administration of the drug Foralumab, an anti-CD3 monoclonal antibody. Investigators ...
Mar 8, 2023
0
111
Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M—which ...
Sep 11, 2022
0
5
A widely used and inexpensive type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most common forms of the disease, according to new findings.
May 24, 2022
0
60
(HealthDay)—Steroids reduce the risk for major adverse kidney outcomes in people with high-risk immunoglobulin A nephropathy (IgAN), but full-dose methylprednisolone increased the risk for serious adverse events, according ...
Nov 16, 2021
0
2
A trio of drugs could delay the progression of metastatic castration-resistant prostate cancer.
Nov 3, 2021
0
12
Two new studies have cast unprecedented light on disease processes in tuberculosis, identifying key genetic changes that cause damage in the lungs and a drug treatment that could speed up recovery.
Jun 15, 2021
0
12
Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of ...
Apr 23, 2021
0
27
The omega-3 fatty acids EPA and DHA work differently against chronic inflammation, according to the results of a small randomized study, suggesting each has its own important role to play in regulating the immune system.
Dec 7, 2020
0
440
A new therapy for metastatic colorectal cancer that has been granted fast-track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.
Nov 20, 2020
0
3
